{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:05:47Z","timestamp":1791896747079,"version":"4.3.4"},"reference-count":59,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA161891"],"award-info":[{"award-number":["1R01CA161891"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5P30CA16087"],"award-info":[{"award-number":["5P30CA16087"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,3,19]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Toll-like receptor (TLR) agonists and radiation therapy hold promise for cancer immunotherapy. We conducted a phase I\/II trial combining topical imiquimod (IMQ, a TLR-7 agonist) and local radiotherapy (RT) in patients with metastatic breast cancer accompanied by longitudinal transcriptional analysis of tumor biopsies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The primary objective of the trial (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01421017\">NCT01421017<\/jats:ext-link>\n                      ) was to assess systemic responses by immune-related response criteria (irRC) after an 8-week cycle of topical IMQ and concurrent local RT (cohort 1). An amendment to the trial added two cohorts, both received one dose of cyclophosphamide (CTX) administered 1 week before study treatment initiation, IMQ\/RT\/CTX (cohort 2) and RT\/CTX control (cohort 3). Cutaneous metastases were prospectively assigned to treatment with IMQ and RT (area A) or IMQ alone (area B). Secondary objectives were safety (Common Terminology Criteria for Adverse Events criteria) and local response in skin metastases. In all IMQ cohorts, tumors were biopsied before treatment and at 2 and 3 weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>31 patients were enrolled (n=12, n=12, and n=7, in cohort 1, 2, and 3, respectively), with 4 out of 24 patients in the IMQ cohorts showing systemic tumor responses (two complete responses (CR) and two partial responses (PR)). No objective responses were observed in the seven patients enrolled in the control arm (RT alone). The treatment was well-tolerated, no grade 4\u20135 treatment-related adverse events occurred and grade 3 AEs were manageable (anemia, local pain, and local ulceration, n=1 each). Local objective responses were observed in 19\/24 (9 CR and 10 PR) and 5\/24 (5 PR) in areas treated with combined IMQ-RT and IMQ alone, respectively (p&lt;0.001). All 24 patients treated with IMQ underwent serial biopsies, and 84 samples yielded sufficient material for transcriptional analyses. These revealed that the presence of a T-helper 1 functional orientation of the tumor microenvironment paralleled by the downregulation of DNA-repair genes was associated with CR after IMQ+RT, but not after IMQ alone. No post-treatment activation of immune-effector functions was observed in stable and progressing lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings support the safety and clinical efficacy of combining topical IMQ with local RT for recurrent breast cancer, with evidence of local and occasional systemic antitumor activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01421017\">NCT01421017<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-011173","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T09:41:12Z","timestamp":1743846072000},"page":"e011173","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct01421017","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01421017","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01421017","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Sylvia","family":"Adams","sequence":"first","affiliation":[{"name":"Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4426-0499","authenticated-orcid":false,"given":"Sandra","family":"Demaria","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Weill Cornell Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darawan","family":"Rinchai","sequence":"additional","affiliation":[{"name":"Sidra Medical and Research Center, Ar-Rayyan, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ena","family":"Wang","sequence":"additional","affiliation":[{"name":"Sidra Medical and Research Center, Ar-Rayyan, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena","family":"Novik","sequence":"additional","affiliation":[{"name":"Department of Medicine, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Oratz","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fenton-Kerimian","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Weill Cornell Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale G","family":"Levine","sequence":"additional","affiliation":[{"name":"Pathology, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Marincola","sequence":"additional","affiliation":[{"name":"TAM Bioscience, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Jin","sequence":"additional","affiliation":[{"name":"National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Stroncek","sequence":"additional","affiliation":[{"name":"National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3758-6976","authenticated-orcid":false,"given":"Judith","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Population Health, NYU Grossman School of Medicine, New York, New York, USA"},{"name":"NYU Grossman School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bedognetti","sequence":"additional","affiliation":[{"name":"Sidra Medicine, Doha, Ad Dawhah, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8227-8924","authenticated-orcid":false,"given":"Silvia Chiara","family":"Formenti","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Weill Cornell Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"key":"2026052108352281000_13.4.e011173.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00604.x"},{"key":"2026052108352281000_13.4.e011173.2","first-page":"949","article-title":"Toll-like receptor agonists in cancer therapy","volume":"1","author":"Adams","year":"2009","journal-title":"Immunotherapy (Los Angel)"},{"key":"2026052108352281000_13.4.e011173.3","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902997"},{"key":"2026052108352281000_13.4.e011173.4","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2007-8-1-r8","article-title":"Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection","volume":"8","author":"Panelli","year":"2007","journal-title":"Genome Biol"},{"key":"2026052108352281000_13.4.e011173.5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1149"},{"key":"2026052108352281000_13.4.e011173.6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-42784-9","article-title":"Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod","volume":"9","author":"Rozenblit","year":"2019","journal-title":"Sci Rep"},{"key":"2026052108352281000_13.4.e011173.7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.877014","article-title":"Cutaneous Breast Cancer Metastasis Is Effectively Treated With Intralesional Interleukin-2 and Imiquimod: A Case Report and Brief Literature Review","volume":"12","author":"Drohan","year":"2022","journal-title":"Front Oncol"},{"key":"2026052108352281000_13.4.e011173.8","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jamaoncol.2016.6007","article-title":"Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial","volume":"3","author":"Salazar","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026052108352281000_13.4.e011173.9","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of Local Radiation Therapy in Cancer Immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"},{"key":"2026052108352281000_13.4.e011173.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00054-6"},{"key":"2026052108352281000_13.4.e011173.11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0926"},{"key":"2026052108352281000_13.4.e011173.12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0984"},{"key":"2026052108352281000_13.4.e011173.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.9793"},{"key":"2026052108352281000_13.4.e011173.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.728.11.2"},{"key":"2026052108352281000_13.4.e011173.15","doi-asserted-by":"publisher","DOI":"10.1038\/nm1622"},{"key":"2026052108352281000_13.4.e011173.16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0265"},{"key":"2026052108352281000_13.4.e011173.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0232-2"},{"key":"2026052108352281000_13.4.e011173.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00149-2"},{"key":"2026052108352281000_13.4.e011173.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.3494"},{"key":"2026052108352281000_13.4.e011173.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0432-4"},{"key":"2026052108352281000_13.4.e011173.21","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1158\/1078-0432.CCR-23-1267","article-title":"Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22-00","volume":"29","author":"Joaquin Garcia","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026052108352281000_13.4.e011173.22","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199607000-00006"},{"key":"2026052108352281000_13.4.e011173.23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10549-017-4570-4","article-title":"Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer","volume":"168","author":"Kwa","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"2026052108352281000_13.4.e011173.24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ijrobp.2007.06.035","article-title":"Multi-institutional review of repeat irradiation of chest wall and breast for recurrent breast cancer","volume":"70","author":"Wahl","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026052108352281000_13.4.e011173.25","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(96)00154-X"},{"key":"2026052108352281000_13.4.e011173.26","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/0360-3016(83)90170-0","article-title":"Tumor control and therapeutic gain with different schedules of combined radiotherapy and local external hyperthermia in human cancer","volume":"9","author":"Arcangeli","year":"1983","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026052108352281000_13.4.e011173.27","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-005-7017-2"},{"key":"2026052108352281000_13.4.e011173.28","first-page":"108","article-title":"Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer","volume":"23","author":"Quan","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"key":"2026052108352281000_13.4.e011173.29","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2089"},{"key":"2026052108352281000_13.4.e011173.30","first-page":"374","article-title":"Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a phase I\/II trial","volume":"8","author":"Kouloulias","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2026052108352281000_13.4.e011173.31","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.1989.7.9.1201","article-title":"Kaposi\u2019s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee","volume":"7","author":"Krown","year":"1989","journal-title":"J Clin Oncol"},{"key":"2026052108352281000_13.4.e011173.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2026052108352281000_13.4.e011173.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"2026052108352281000_13.4.e011173.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2008.03.002"},{"key":"2026052108352281000_13.4.e011173.35","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/s41591-023-02324-5","article-title":"An integrated tumor, immune and microbiome atlas of colon cancer","volume":"29","author":"Roelands","year":"2023","journal-title":"Nat Med"},{"key":"2026052108352281000_13.4.e011173.36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000617","article-title":"Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response","volume":"8","author":"Roelands","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026052108352281000_13.4.e011173.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0309-1"},{"key":"2026052108352281000_13.4.e011173.38","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1253654","article-title":"Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis","volume":"6","author":"Hendrickx","year":"2017","journal-title":"Oncoimmunology"},{"key":"2026052108352281000_13.4.e011173.39","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02397-z","article-title":"The immune landscape of solid pediatric tumors","volume":"41","author":"Sherif","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"2026052108352281000_13.4.e011173.40","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003687","article-title":"Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature","volume":"10","author":"Bertucci","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026052108352281000_13.4.e011173.41","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-023-04463-2","article-title":"Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer","volume":"21","author":"Mogenet","year":"2023","journal-title":"J Transl Med"},{"key":"2026052108352281000_13.4.e011173.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(00)01724-2"},{"key":"2026052108352281000_13.4.e011173.43","doi-asserted-by":"publisher","DOI":"10.1586\/erv.10.55"},{"key":"2026052108352281000_13.4.e011173.44","doi-asserted-by":"publisher","DOI":"10.1038\/74546"},{"key":"2026052108352281000_13.4.e011173.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.10.003"},{"key":"2026052108352281000_13.4.e011173.46","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-015-0620-6","article-title":"Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy","volume":"16","author":"Angelova","year":"2015","journal-title":"Genome Biol"},{"key":"2026052108352281000_13.4.e011173.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.008"},{"key":"2026052108352281000_13.4.e011173.48","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190"},{"key":"2026052108352281000_13.4.e011173.49","doi-asserted-by":"crossref","DOI":"10.1172\/JCI138740","article-title":"Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control","volume":"131","author":"Lhuillier","year":"2021","journal-title":"J Clin Invest"},{"key":"2026052108352281000_13.4.e011173.50","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.1.776"},{"key":"2026052108352281000_13.4.e011173.51","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20071190"},{"key":"2026052108352281000_13.4.e011173.52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2004.30091.x"},{"key":"2026052108352281000_13.4.e011173.53","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.3.273"},{"key":"2026052108352281000_13.4.e011173.54","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004797","article-title":"Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration","volume":"10","author":"Higgs","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026052108352281000_13.4.e011173.55","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4143\/crt.2014.46.2.194","article-title":"Case series of different onset of skin metastasis according to the breast cancer subtypes","volume":"46","author":"Cho","year":"2014","journal-title":"Cancer Res Treat"},{"key":"2026052108352281000_13.4.e011173.56","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2023.2232299","article-title":"The prognostic significance of skin involvement in breast cancer patients with chest wall recurrence","volume":"55","author":"Zhou","year":"2023","journal-title":"Ann Med"},{"key":"2026052108352281000_13.4.e011173.57","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162260","article-title":"Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases","volume":"133","author":"Korpics","year":"2023","journal-title":"J Clin Invest"},{"key":"2026052108352281000_13.4.e011173.58","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1790"},{"key":"2026052108352281000_13.4.e011173.59","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-44195-x","article-title":"Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial","volume":"14","author":"Altorki","year":"2023","journal-title":"Nat Commun"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-011173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:35:39Z","timestamp":1779377739000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-011173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":59,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,5]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/jitc-2024-011173"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-011173","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}